A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of QGE031 compared to omalizumab in patients with
allergic asthma. Each treatment's effect in changing the concentration of inhaled allergen
that is required to elicit a 15% fall in the forced expiratory volume in one second (FEV1) at
12 weeks compared to baseline will be evaluated.